Saturday 23 November 2024

Pharma & Biotech Mergers & Acquisitions News

Decoding big pharmas’ next move in a more complex China
Pharmaceutical
Decoding big pharmas’ next move in a more complex China
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai.   18 November 2024
Biotechnology
BioNTech to boost oncology offering with buy of Biotheus
13 November 2024
Biotechnology
Gene specialist Trace takes on ALS with $101 million
12 November 2024
Biotechnology
AlloVir announces merger with Kalaris Therapeutics
8 November 2024
Pharmaceutical
EU sets date for decision on proposed $16.5 billion Catalent buy
5 November 2024

Today's issue

Otsuka gains global licensing rights from Ionis to ulefnersen
Pharmaceutical
Otsuka gains global licensing rights from Ionis to ulefnersen
23 November 2024
Biotechnology
Anti-CD20 MAb Rituxan approved for ITP in Japan
23 November 2024
Biotechnology
J&J powers on with Tremfya with UC SC filing
22 November 2024
Biotechnology
Takeda launches Fruzaqla in Japan
22 November 2024
Biotechnology
CStone out-licenses sugemalimab rights in MENA region
22 November 2024
Biotechnology
China's regulator to review Akeso's checkpoint blocker
22 November 2024
Biotechnology
Paragon Therapeutics appoints first chief executive
22 November 2024
Reset all filters
Refine Search

Latest Mergers & Acquisitions News & Features

Biotechnology
Aizen hopes AI will help make mirror peptides a reality
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX.   21 November 2024
Biotechnology
VBI recalls PreHevbrio and winds down operations
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations.   19 November 2024
Biotechnology
The week in pharma: action, reaction and insight – week to November 15
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros.   17 November 2024
Biotechnology
Halozyme sets out offer to acquire Evotec
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion).   15 November 2024
Biotechnology
BeiGene signals global outlook with new name
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration.   15 November 2024
Biotechnology
BioNTech to boost oncology offering with buy of Biotheus
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE).   13 November 2024
Biotechnology
Gene specialist Trace takes on ALS with $101 million
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS).   12 November 2024
Biotechnology
AlloVir announces merger with Kalaris Therapeutics
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics.   8 November 2024
Biotechnology
Nektar sells its PEGylation reagent manufacturing business
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility.   5 November 2024
Biotechnology
GlycoMimetics soars on news of M&A deal with Crescent Biopharma
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors.   30 October 2024
Biotechnology
Dr Falk Pharma acquires spinout Kynos Therapeutics
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases.   29 October 2024
Biotechnology
AbbVie punts $1.4 billion to buy early-stage Alzheimer’s drug developer Aliada
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.   29 October 2024
Biotechnology
Ottimo Pharma launches under former Seagen chief exec
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders.   28 October 2024
Biotechnology
The week in pharma: action, reaction and insight – week to October 25
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline.   27 October 2024
Biotechnology
Lyell Immunopharma to acquire ImmPACT Bio
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio.   26 October 2024
Biotechnology
Mankind pays $1.65 billion for Bharat Serums and Vaccines
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market.   24 October 2024
Biotechnology
Ocuphire buys Opus Genetics, grows gene therapy pipeline
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases.   24 October 2024
Biotechnology
Merck & Co buys Modifi Biosciences
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co   23 October 2024
Biotechnology
Merger to create global Treg company
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge.   18 October 2024
Biotechnology
Lundbeck forking out $2.6 billion to acquire Longboard Pharma
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals.   15 October 2024
Biotechnology
Merck KGaA acquires Indian bioscience company Bagalore Genei
Joining the move into the BRIC (Brazil, Russia, India and China) countries, German drug major Merck KGaA has announced the acquisition of Bangalore Genei (India) Private Ltd. (BGIP) by its wholly-owned subsidiary in India, Merck Specialities Private, from the Sanmar Group. By combining BGIP's activities with Merck's existing bioscience business, the German firm says it will become one of the leading bioscience companies in India. Financial terms of the transaction were not disclosed.   14 October 2009
Biotechnology
The Future of Japanese Bioventures by P Reed Maurer
It is difficult to be optimistic about the future of Japanese bioventures. To date the track record is miserable. Out of the roughly 600 bioventures, only 22 managed to go public. 20 of these are analyzed in the chart below. Please note the following:   13 October 2009
Biotechnology
Phyton Biotech acquires assets of Natural Pharmaceuticals
USA-based Phyton Biotech, an affiliate of Phyton Inc, has purchased the assets of Natural Pharmaceuticals, a US manufacturer of oncology drug active pharmaceutical ingredients (APIs).   13 October 2009
Biotechnology
Onyx to buy Proteolix for as much as $850 million to get blood cancer drug
California, USA-based Proteolix has agreed to a takeover bid from Onyx Pharmaceuticals, valuing the firm at a potential $851 million based on upfront and milestone payments. Proteolix' lead compound is carfilzomib, a proteasome inhibitor currently in multiple clinical trials, including an advanced Phase IIb studies for patients with relapsed and refractory multiple myeloma.   12 October 2009

Company Spotlight

A Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.




Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze